Abstract : In this study, the effects of ultra-low-dose hormone therapy (Ultra-LD HT) are assessed using a shock model. It is believed that shocks follow a Poisson process. The effects of estrogen can cause osteoporosis if the interval between two consecutive shocks is less than a specific threshold. Since bone turnover markers (BTM) in postmenopausal women decrease as a result of 17β-estradiol 0.5 mg and norethisterone acetate 0.1 mg (E2 0.5/NETA 0.1) dosages, we suggest that the successive threshold values increase geometrically for worsening stress. Additionally, An expanding geometric sequence is formed by the recovery durations following osteoporosis. After BTM loss from 17β-estradiol and norethisterone acetate, we propose that the succeeding threshold values decline geometrically, with the subsequent recovery times creating a diminishing geometric sequence, in order to improve BTM. After the Nth failure, the dosage of this study looks at how ultra-low-dose hormone therapy (Ultra-LD HT) works, 17β-estradiol is changed to a fresh, similar one at the Nth shock. We explicitly determine an optimal dosage change, denoted as N*, for each scenario of improving BTM and deteriorating stress. This change is intended to minimize the long-run average dosage per unit time by calculating the average expectations for bone resorption markers, such as C-Telopeptide of type I collagen (CTX-I) and N-telopeptide crosslinked of type I collagen (NTX), and bone formation markers, such as N-terminal properties of type I procollagen (PINP) and bone-specific alkaline phosphatase (BSAP) and N-terminal procollagen (PINP). These were assessed before and after 12 and 24 weeks of treatment, and compared with a placebo.